For every person living with disabling primary headaches, recent translational success has heralded a welcome advance in therapeutic options. After years of research and some wrong turns along the way, it is reassuring that a number of promising targets have advanced the journey from bench to bedside. The first approval was monoclonal antibodies to target calcitonin gene-related peptide (CGRP) or its receptor (erenumab, fremanezumab and galcanezumab) for migraine prevention. In terms of acute therapy, both the serotonin (5-HT) 5-HT_1F receptor agonist (lasmiditan) and small molecule CGRP receptor antagonists (ubrogepant and rimegepant) received FDA approval. Despite this success, there is little time to rest on our laurels, as there remains a need to generate a greater understanding of all anti-migraine therapies, to include their clinical mechanisms of action and their potential unwanted side effects/risk factors. Unfortunately, a common theme has emerged for several drugs including triptans, ergotamine, caffeine, paracetamol (acetaminophen) and opioids (1–3), whereby their excessive use leads to an increased risk of increasing migraine frequency and the development of a chronic state termed medication overuse headache (MOH) (4). Importantly, MOH appears a particular characteristic of headache disorders, with people who have a personal or family history of headaches most vulnerable, suggesting a potential genetic component (5).

中文翻译：

---

药物过度使用性头痛：新型急性抗偏头痛药物的不同作用。

对于每个患有致残性原发性头痛的人来说，最近的转化成功预示着治疗选择的可喜进步。经过多年的研究和沿途的一些错误转变，令人欣慰的是，一些有希望的目标已经从板凳到床边。第一个批准是针对降钙素基因相关肽 (CGRP) 或其受体（erenumab、fremanezumab 和 galcanezumab）的单克隆抗体，用于预防偏头痛。在急性治疗方面，血清素 (5-HT) 5-HT _1F受体激动剂（lasmiditan）和小分子 CGRP 受体拮抗剂（ubrogepant 和 rimegepant）获得 FDA 批准。尽管取得了这一成功，但我们几乎没有时间可以固步自封，因为仍然需要对所有抗偏头痛疗法有更深入的了解，包括它们的临床作用机制及其潜在的不良副作用/风险因素。不幸的是，包括曲坦类药物、麦角胺、咖啡因、扑热息痛（对乙酰氨基酚）和阿片类药物 (1-3) 在内的几种药物出现了一个共同的主题，因此过度使用它们会导致偏头痛频率增加和发展为称为慢性病的风险增加药物过度使用性头痛 (MOH) (4)。重要的是，MOH 似乎是头痛疾病的一个特殊特征，